Moomoo AI 已提取核心信息
John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 24, 2024, involving the acquisition of 29 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 141 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.
John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 24, 2024, involving the acquisition of 29 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 141 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.
T2 Biosystems, Inc.（TTOO）首席财务官约翰·斯普拉格于2024年2月24日执行了一项交易，涉及收购29股普通股。该交易被归类为 “M”，表示行使或转换衍生证券。在这笔交易之后，Sprague在该公司的直接持有量增加到总共141股普通股。该行动反映了首席财务官对该公司的持续投资，这表明了对T2 Biosystems未来业绩的潜在信心。
T2 Biosystems, Inc.（TTOO）首席财务官约翰·斯普拉格于2024年2月24日执行了一项交易，涉及收购29股普通股。该交易被归类为 “M”，表示行使或转换衍生证券。在这笔交易之后，Sprague在该公司的直接持有量增加到总共141股普通股。该行动反映了首席财务官对该公司的持续投资，这表明了对T2 Biosystems未来业绩的潜在信心。
有用
没用
